Home » Stocks » NMTR

9 Meters Biopharma, Inc. (NMTR)

Stock Price: $1.07 USD -0.02 (-1.83%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $1.05 -0.02 (-1.87%) Nov 27, 4:49 PM

Stock Price Chart

Key Info

Market Cap 160.85M
Revenue (ttm) n/a
Net Income (ttm) -65.44M
Shares Out 150.32M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $1.07
Previous Close $1.09
Change ($) -0.02
Change (%) -1.83%
Day's Open 1.09
Day's Range 1.04 - 1.10
Day's Volume 1,470,088
52-Week Range 0.39 - 1.11

More Stats

Market Cap 160.85M
Enterprise Value 149.78M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 150.32M
Float n/a
EPS (basic) -0.97
EPS (diluted) -0.97
FCF / Share -0.12
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.16M
Short Ratio 2.55
Short % of Float n/a
Beta -0.40
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 40.17
Revenue n/a
Operating Income -56.28M
Net Income -65.44M
Free Cash Flow -16.22M
Net Cash 11.07M
Net Cash / Share 0.07
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -123.93%
ROE -42,818.92%
ROIC 698.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.00*
(273.83% upside)
Low
3.00
Current: $1.07
High
5.00
Target: 4.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue---4.078.2711.34
Revenue Growth----50.82%-27.13%-
Gross Profit---0.740.430.23
Operating Income-24.28-18.22-11.17-5.94-6.46-6.68
Net Income-27.05-24.16-11.61-6.21-8.74-11.06
Shares Outstanding33.3324.7611.890.550.330.28
Earnings Per Share-0.81-0.98-0.98-11.26-26.50-39.50
Operating Cash Flow-17.97-15.17-5.10-8.43-1.73-7.45
Capital Expenditures-0.01-0.01-0.04---
Free Cash Flow-17.98-15.18-5.14-8.43-1.73-7.45
Cash & Equivalents4.675.800.361.450.120.10
Total Debt3.185.208.570.043.725.09
Net Cash / Debt1.480.61-8.221.42-3.60-4.99
Assets5.306.450.806.464.726.41
Liabilities14.9110.1112.973.9810.4111.40
Book Value-9.61-3.66-12.172.49-5.69-4.99
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name 9 Meters Biopharma, Inc.
Country United States
Employees 8
CEO John Temperato

Stock Information

Ticker Symbol NMTR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NMTR

Description

9 Meters Biopharma, a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.